InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Company profile
Website
CEO
Niels Christoph Riedemann
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Black Nickel Acquisition Corp I
SEC CIK
Corporate docs
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
7 Aug 15
8-K
InferX Corporation Announces Alliance Agreement with e-Discovery/Technology Firm Crossfield Data Services; Michael Deale Appointed InferX Acting EVP
6 Aug 13
10-Q
2012 Q3
Quarterly report
5 Aug 13
10-Q
2012 Q2
Quarterly report
10 Jun 13
10-Q
2012 Q1
Quarterly report
23 May 13
10-K
2011 FY
Annual report
27 Dec 12
8-K
InferX Corporation Executive Management Team Expanded; Paul B. Silverman Joins as CEO and President; Carl Eckstein Joins Board of Directors
27 Dec 12
8-K
Changes in Control of Registrant
23 Jul 12
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
13 Apr 12
NT 10-K
Notice of late annual filing
2 Apr 12
Latest ownership filings
No filings